DOI: 10.4244/EIJV13I17A341

Reply to the letter to the editor by Yaeger regarding the article “In vivo validation of mathematically derived fractional flow reserve for assessing haemodynamics of coronary tandem lesions”

We appreciate the interest in our article1. The author raised the issues of the driving force for myocardial flow, the flow ratio estimation, and the procedural order. Also, the author suggested that the application of the prediction model in Yaeger2 would improve the outcomes of FFR prediction.

Spaan et al3 showed that, even without collateral flows, (Pd–Pv)/(Pa–Pv) overestimates the coronary flow ratio (QS/QN) and the microvascular resistance (Rmin) increases as the distal pressure (Pd) falls. To build an equation to describe the P–Q relationship better, we introduced “R” corresponding to the inverse of the slope for Q vs. Pd–Pw, instead of using a constant microvascular resistance (Figure4 in Spaan et al3). The flow ratios to branches, in the same regard, were estimated using anatomical metrics. Because “R” in our mathematical derivation is dimensionally equivalent to the resistance in electronic circuit modelling, we called it “resistance”.

For determining the procedural order, previous studies have recommended that treatment of the stenosis with greater pressure or FFR gradient during pressure wire pullback should be prioritised4, as addressed in the introduction of our article1. Please remember that the objective of our work was to propose a better method for predicting more severe lesions.

The prediction model of Yaeger2 was examined and the outcomes are listed in Table 1. The mean error was 0.057±0.059 and the mean absolute error was 0.063±0.052. In the Appendix, please find the translation of Yaeger’s prediction model2 to the notations in our derivation.

Appendix. Translation of Yaeger’s prediction model to the notations in the derivation by Kweon et al

For simplicity, abbreviations are used as follows.

FFRapp(LM)=a

FFRtrue(LM)=b

FFRapp(LAD) =FFRtrue(LAD)=c Eq (*1)

FFRreal(LM)=d

FFRreal(LAD)=e

From the pullback measurement, FFRapp(LM) and FFRapp(LAD) are obtained. For the comparison with our mathematical model, we rephrased the equations in Yaeger2 as functions of “a” and “c” as follows.

Equation (19) in Yaeger2 is:

Using the abbreviations above, it becomes:

Eq (*2)

By multiplying both numerator and denominator by 2b, we can get:

.

By multiplying both sides by the denominator, it becomes:

a(1+b+c–bc)=2b and a(1+c)=b(ac–a+2).

Subsequently, b can be expressed as:

. Eq (*3)

Equation (23) in Yaeger2 is:

.

Using the abbreviations above, it becomes:

.

Using the expression in Eq (*3), we can get:

.

Using the notations in Yaeger2, the prediction equation for LAD treatment becomes:

.

Equation (34) for the LM treatment in Yaeger2 is:

.

Using the abbreviations above, it becomes:

.

Using the expression in Eq (*2), we can get:

e=ac.

Using the notations in Yaeger2, the prediction equation for LM treatment becomes:

FFRreal (LAD)=FFRapp (LM)×FFRtrue (LAD).

Using the notations in our derivation, the equations above are translated as follows:

for proximal treatment,

for distal treatment.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Supplementary data

Both of the letters to the Editor disputing the paper, “Invivo validation of mathematically derived fractional flow reserve for assessing haemodynamics of coronary tandem lesions”1, together with all further correspondence can be found online in the Supplementary data.

To read the full content of this article, please download the PDF.

Volume 13 Number 17
Apr 20, 2018
Volume 13 Number 17
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV12I11A219 Dec 9, 2016
FFR in daily clinical practice: from “Prêt-à-Porter” to “Haute Couture”
Finet G and Rioufol G
free

Clinical research

10.4244/EIJ-D-18-00668 Oct 18, 2019
Personalised fractional flow reserve: a novel concept to optimise myocardial revascularisation
Gosling R et al
free
Trending articles
225.68

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
105.78

Expert consensus

10.4244/EIJ-E-22-00018 Dec 4, 2023
Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations
Lunardi M et al
free
77.85

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
68.7

Clinical research

10.4244/EIJ-D-21-00545 Sep 20, 2022
Coronary lithotripsy for the treatment of underexpanded stents: the international; multicentre CRUNCH registry
Tovar Forero M et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
45.3

Clinical research

10.4244/EIJ-D-18-01126 Aug 29, 2019
New-generation mechanical circulatory support during high-risk PCI: a cross-sectional analysis
Ameloot K et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved